Novo Nordisk attempts to acquire weight-loss drug company Metsera during government shutdown, potentially avoiding FTC ...

All of this has weighed on stock performance, leaving the shares down almost 50% over the past three years. Considering this, ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

Trump-Xi truce talks, Nvidia’s $5T milestone, Big Tech earnings, and Musk’s $1T showdown headline a packed week.

Pfizer has decided to sue Metsera and Novo over $8.5B bid, citing antitrust risks and asserting regulatory advantage.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

The top seven customers of the hard-drive company have provided purchase orders through at least the first half of next year. The company said it is on track to meet its advisor retention goals for ...

Pfizer Inc. sued Metsera Inc. and rival drugmaker Novo Nordisk A/S to block the Danish company’s rival bid for the obesity ...

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom.

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining Novo's superior bid offer. Pfizer seeks a court order to prevent Metsera ...

The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.